Anavex Life Sciences Corp (AVXL)

[boi568]

There are apparently two ways to categorize the 0.5 CDR-G result -- as either AD Stage 2 or Stage 3. The question then becomes, which way is the FDA using it for purposes of its draft guidance? Is the Agency using it in a way (as Stage 3) that would largely make its draft guidance ineffective for most clinical trials, or is the FDA using it (as Stage 2) in a way that preserves the utility of the CDR-G scale?

I think the question answers itself.